Search

Displaying results 2501 - 2510 of 5263 in total
  1. Drug

    Diphenoxylate

    go.drugbank.com/drugs/DB01081
    ApprovedIllicitInvestigational

    It has little or no analgesic activity. … This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.

  2. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical

  3. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [L39705] Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors … [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed

  4. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries.

    Synonyms: N-Lysinomethyltetracycline, N2-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline
  5. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003] … [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen.

  6. Drug

    Streptokinase

    go.drugbank.com/drugs/DB00086
    ApprovedInvestigationalWithdrawn

    Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.

  7. Drug

    Estrone sulfate

    go.drugbank.com/drugs/DB04574
    Approved

    Estrone sulfate (as estropipate) is a form of estrogen.

  8. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    signals from circulating leptin. … The high sustained concentrations of leptin from the enlarged fat stores result in the cells that respond to leptin becoming desensitized.

  9. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    [L34440] Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was … [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.

  10. Drug

    Bexarotene

    go.drugbank.com/drugs/DB00307
    ApprovedInvestigational

    Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.